Stock Events

Stock Events

ZyVersa Therapeutics 

$0.21
22
+$0+2.5% Thursday 19:53

Statistics

Day High
0.2
Day Low
0.16
52W High
1.94
52W Low
0.11
Volume
9,575
Avg. Volume
73,390
Mkt Cap
1.66M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

19MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Next
Next
-2.73
-1.22
0.29
1.79
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2021
2022
2023
2024
0Revenue
-18.83MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ZVSA. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals focuses on creating new treatments for inflammatory diseases, directly competing with ZyVersa's inflammatory disease segment.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals develops therapies for inflammatory conditions, overlapping with ZyVersa's product pipeline.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences has a strong presence in the development of treatments for inflammatory and renal diseases, areas ZyVersa is targeting.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie has a diverse portfolio in immunology and inflammatory diseases, competing with ZyVersa's therapeutic areas.
AMGEN
AMGN
Mkt Cap160.66B
Amgen's focus on innovative therapeutics for inflammatory diseases places it in direct competition with ZyVersa.
Biogen
BIIB
Mkt Cap22.63B
Biogen's investment in novel therapies for neurological and inflammatory diseases makes it a competitor.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its pharmaceutical division Janssen, competes in the inflammatory disease space.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has a broad range of products for inflammatory conditions, directly competing with ZyVersa's focus areas.
Novartis
NVS
Mkt Cap237.61B
Novartis AG engages in the research, development, and marketing of healthcare products, including treatments for inflammatory diseases.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca operates in various therapeutic areas, including inflammation, competing with ZyVersa's development programs.

About

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.
Show more...
CEO
Mr. Stephen C. Glover
Employees
7
Country
US
ISIN
US98987D3008

Listings

OTC Link
US
ZVSA

0 Comments

Share your thoughts

FAQ

What is ZyVersa Therapeutics stock price today?▼
The current price of ZVSA is $0.21 USD — it has increased by +2.5% in the past 24 hours. Watch ZyVersa Therapeutics stock price performance more closely on the chart.
What is ZyVersa Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange ZyVersa Therapeutics stocks are traded under the ticker ZVSA.
Is ZyVersa Therapeutics stock price growing?▼
ZVSA stock has risen by +5.67% compared to the previous week, the month change is a -21.15% fall, over the last year ZyVersa Therapeutics has showed a -66.77% decrease.
What is ZyVersa Therapeutics market cap?▼
Today ZyVersa Therapeutics has the market capitalization of 1.66M
When is the next ZyVersa Therapeutics earnings date?▼
ZyVersa Therapeutics is going to release the next earnings report on May 19, 2026.
What is ZyVersa Therapeutics revenue for the last year?▼
ZyVersa Therapeutics revenue for the last year amounts to 0 USD.
What is ZyVersa Therapeutics net income for the last year?▼
ZVSA net income for the last year is -18.83M USD.
How many employees does ZyVersa Therapeutics have?▼
As of April 04, 2026, the company has 7 employees.
In which sector is ZyVersa Therapeutics located?▼
ZyVersa Therapeutics operates in the Health Care sector.
When did ZyVersa Therapeutics complete a stock split?▼
The last stock split for ZyVersa Therapeutics was on April 26, 2024 with a ratio of 1:10.
Where is ZyVersa Therapeutics headquartered?▼
ZyVersa Therapeutics is headquartered in Weston, US.